MADRIGAL PHARMACEUTICALS, INC.
MDGLNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $958.4M | $180.1M | $0 | $0 | $0 | $0 |
| Operating income | −$300.1M | −$497.9M | −$380.5M | −$293.6M | −$242.5M | −$206.7M |
| Net income | −$288.3M | −$465.9M | −$373.6M | −$295.4M | −$241.8M | −$202.2M |
| Total assets | $1.26B | $1.04B | $640.5M | $362.6M | $273.3M | $287.0M |
| Total liabilities | $656.9M | $287.9M | $235.2M | $165.2M | $77.2M | $47.0M |
| Equity | $602.7M | $754.4M | $405.3M | $197.4M | $196.1M | $240.0M |
| EPS (diluted) | $-12.85 | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 |
| Shares out. | 22.1M | 19.9M | 18.1M | 17.1M | 16.0M | 15.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −31.3%
- Net margin
- −30.1%
- Return on equity
- −47.8%
- Return on assets
- −22.9%
- Return on capital (ROCE)
- −31.6%
- Liabilities / assets
- 52.2%
- Debt / equity
- 1.09×
- Book value / share
- $27.30
- Revenue growth (YoY)
- 432.1%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -1.18distress
- Accruals / assets
- −7.8%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- REZDIFFRAMar 14, 2024
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2026-12A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)
- Phase 3Active Not Recruitingreadout ~2027-03A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
- Phase 3Active Not Recruitingreadout ~2028-01A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
- Phase 2Recruitingreadout ~2028-08Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Soergel DavidOfficer — Chief Medical Officer | Jun 1, 2026 | Sell | 1,042 | $495.74 |
| Levy Richard SDirector | May 22, 2026 | Sell | 40 | $506.68 |
| Soergel DavidOfficer — Chief Medical Officer | May 18, 2026 | Sell | 844 | $515.90 |
| Dier MardiOfficer — EVP and CFO | Mar 4, 2026 | Grant | 5,215 | $0.00 |
| Sibold William JohnOfficer — President and CEO | Mar 4, 2026 | Grant | 14,995 | $0.00 |
| Kelley Shannon TOfficer — General Counsel | Mar 4, 2026 | Grant | 4,017 | $0.00 |
| Huntsman CaroleOfficer — Chief Commercial Officer | Mar 4, 2026 | Grant | 3,989 | $0.00 |
| Taub RebeccaDirector | Mar 6, 2026 | Sell | 491 | $431.94 |
| Soergel DavidOfficer — Chief Medical Officer | Mar 4, 2026 | Grant | 4,374 | $0.00 |
| Dier MardiOfficer — EVP and CFO | Mar 2, 2026 | Sell | 1,183 | $427.21 |
| Levy Richard SDirector | Feb 23, 2026 | Option exercise | 2,500 | $7.36 |
| Levy Richard SDirector | Jan 26, 2026 | Option exercise | 4,000 | $16.46 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.9M | 12.3 | +1.1% |
| Apr 30, 2026 | 3.9M | 16.5 | -4.0% |
| Apr 15, 2026 | 4.0M | 12.7 | +2.6% |
| Mar 31, 2026 | 3.9M | 9.1 | -0.5% |
| Mar 13, 2026 | 3.9M | 13.9 | +5.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 6, 2026
- Director / officer changeApr 28, 2026
- Results of operationsFeb 19, 2026
- Entered a material agreementJan 30, 2026
- Director / officer changeDec 11, 2025
- Results of operationsNov 4, 2025
- Results of operationsAug 5, 2025
- Regulation FD disclosureJul 30, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4FORM 4Jun 1, 2026
- 144Jun 1, 2026
- 4FORM 4May 22, 2026
- 144May 22, 2026
- 4FORM 4May 18, 2026
- 144May 18, 2026
- SCHEDULE 13G/AMay 15, 2026
- SCHEDULE 13G/AMay 15, 2026
- 10-QMay 6, 2026
- 8-KMay 6, 2026
- 8-KApr 28, 2026
- ARSApr 28, 2026
- DEFA14AApr 28, 2026
- DEF 14ADEFINITIVE PROXY STATEMENTApr 28, 2026
- SCHEDULE 13G/AMar 27, 2026
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.